Navigation Links
Advance in regenerative medicine could make reprogrammed cells safer while improving their function
Date:8/1/2013

NEW YORK (Aug. 1, 2013) -- The enormous promise of regenerative medicine is matched by equally enormous challenges. But a new finding by a team of researchers led by Weill Cornell Medical College has the potential to improve both the safety and performance of reprogrammed cells.

The researchers' study, published in today's issue of the journal Nature, found that an enzyme, activation-induced cytidine deaminase (AID), helps in the process that changes an adult human cell into an induced pluripotent stem cell (iPS cell). These iPS cells can then be developed into any kind of cell needed to therapeutically restore tissues and organs.

The finding settles an ongoing controversy regarding use of AID to reprogram cells, says the study's senior investigator, Dr. Todd Evans, vice chair for research and professor of cell and developmental biology in the Department of Surgery at Weill Cornell Medical College.

"The dispute was whether AID is required to make iPS cells, and we found that the enzyme does make reprogramming very efficient, although it is not absolutely necessary," says Dr. Evans, an internationally-recognized authority on regenerative medicine. "In fact, we plan to test if reprogramming iPS cells without AID may even be helpful."

One reason is that AID can cause genetic mutations that can lead to cancer. AID is best known as a master regulator of antibody diversity in B cells, and in order to create varied types of beneficial antibodies, it routinely mutates antibody genes. But sometimes the process goes awry, resulting in development of B cell lymphoma, Dr. Evans says. "That leads us to believe that if you can reprogram cells without AID, it could reduce risk of potential mutations, and thus be safer."

iPS Cells Without AID Remember What They Once Were

In order to push a cell, such as a fibroblast, to revert to an iPS cell, the epigenetic "markers" that define an adult cell must be removed. "All cells of the body have the same genes, but they are used differently in different tissues," Dr. Evans explains. "If an undifferentiated cell becomes a heart cell, somehow it has to lock in and stabilize that particular adult phenotype and not forget what it is."

One way that function is accomplished is by placing a methylation group on top of certain genes that activate other cell destinations -- such as to become a liver cell -- usually switching those genes off. "We have known how these marks are put on genes, but we didn't know how they were taken off in the process of pushing an adult cell to revert back to a stem-cell-like state," Dr. Evans says.

Dr. Evans and his colleagues found that the AID enzyme removed those epigenetic markers.

They then created a mouse that did not produce AID to see if the animal's adult fibroblast cells could be pushed back to iPS cells. "If you need AID to reprogram the cells, you shouldn't be able to do it, or do it well."

Surprisingly, they found that the cells at first seemed to want to reprogram even faster than normal cells, but most never fully reverted to a stem-cell-like state. "They eventually crashed and differentiated back into a fibroblast," Dr. Evans says. "What that meant is that they never cleared their memory of being a fibroblast cell. AID efficiently removes that epigenetic memory, smoothing the way for a cell to morph into an undifferentiated state."

But some of the mouse adult fibroblasts lacking AID -- those that Dr. Evans says they "babysat" -- did become iPS cells.

Despite the fact that reprogramming adult cells without AID is inefficient, the researchers say that the method may offer another advantage besides increased safety.

"It might be useful to allow epigenetic memory to be retained," Dr. Evans says. "If you want to make new cardiac cells to repair a patient's heart, it might be better to start with a cardiac cell and push it to become an iPS cell, from which other cardiac cells could be made. If these cells remember they were cardiac cells, they might make a better heart cell than if they came from reprogrammed fibroblasts."


'/>"/>

Contact: John Rodgers
jdr2001@med.cornell.edu
646-317-7401
Weill Cornell Medical College
Source:Eurekalert

Related biology news :

1. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
2. MARC travel awards announced for the AAI 2013 Advanced Course in Immunology Meeting
3. Advance Research Associates Partners With MedNet Solutions
4. New sickle cell anemia therapy advances to Phase II clinical trials
5. OHSU scientists advance understanding of brain receptor; may help fight neurological disorders
6. Engineered stem cell advance points toward treatment for ALS
7. NSF approves planning grant for Center for Advanced Research in Drying
8. New advances in the management of patients with cirrhosis
9. Ludwig presents advancements in immunotherapy and epigenetics at the American Association for Cancer Research Annual Meeting
10. Ludwig advancements in immunotherapy and epigenetics top scientific program at AACR
11. Research advances therapy to protect against dengue virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... and SANDY, Utah , ... which operates the highest sample volume laboratory in ... Genomics and UNIConnect, leaders in clinical sequencing informatics and ... launch of a project to establish the informatics infrastructure ... NSO has been contracted by the Ontario ...
(Date:3/18/2016)... March 18, 2016 --> ... Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and Perimeter ... companies in the border security market and the continuing migration ... Europe has led visiongain to publish ... success. --> defence & security companies in ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)...  Regular discussions on a range of subjects including policies, ... entities said Poloz. Speaking at a lecture to ... he pointed to the country,s inflation target, which is set ... "In certain areas there needs ... economic goals, why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
Breaking Biology Technology: